Document Detail


Leukodepletion and aprotinin improve clinical outcome after extracorporeal circulation.
MedLine Citation:
PMID:  11334206     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Most cardiac operations involve the use of extracorporeal circulation with its attendant systemic inflammatory response syndrome. Many anti-inflammatory strategies hold promise for reducing the associated morbidity of cardiopulmonary bypass. The application of pharmacological and mechanical strategies to control this inflammatory response now has demonstrable clinical benefit. The additional costs of these successful strategies are offset by the economic savings and improved quality of care.
Authors:
J P Gott
Related Documents :
25327166 - Payment rates for personal care assistants and the use of long-term services and suppor...
1589716 - Cardiac arrest during treatment of pneumocystis carinii pneumonia with intravenous pent...
15584686 - Perioperative care of the surgical patient.
8625626 - Acute hemodynamic and neurohoromonal effects of furosemide in critically ill pediatrics...
11880726 - Adolescents with cancer: access to clinical trials and age-appropriate care.
3951266 - Usmgs versus fmgs. are there performance differences in the ambulatory care setting?
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Perfusion     Volume:  16 Suppl     ISSN:  0267-6591     ISO Abbreviation:  Perfusion     Publication Date:  2001 Mar 
Date Detail:
Created Date:  2001-05-03     Completed Date:  2002-01-14     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8700166     Medline TA:  Perfusion     Country:  England    
Other Details:
Languages:  eng     Pagination:  5-9     Citation Subset:  IM    
Affiliation:
Fuqua Heart Center, Piedmount Hospital, Atlanta, Georgia 30309, USA. gottjp@aol.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenal Cortex Hormones / administration & dosage
Antifibrinolytic Agents / administration & dosage,  economics,  pharmacology
Aprotinin / administration & dosage,  economics,  pharmacology*
Cardiopulmonary Bypass / adverse effects,  economics,  methods,  mortality
Coated Materials, Biocompatible
Costs and Cost Analysis
Extracorporeal Circulation / economics,  mortality,  standards*
Fibrin Fibrinogen Degradation Products / metabolism
Filtration
Heparin
Humans
Inflammation / drug therapy,  etiology,  prevention & control
Leukapheresis*
Serine Proteinase Inhibitors / administration & dosage,  economics,  pharmacology*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Antifibrinolytic Agents; 0/Coated Materials, Biocompatible; 0/Fibrin Fibrinogen Degradation Products; 0/Serine Proteinase Inhibitors; 0/fibrin fragment D; 9005-49-6/Heparin; 9087-70-1/Aprotinin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Conditioned blood reperfusion during angioplasty (CoBRA) treatment of acute myocardial infarction.
Next Document:  Filtration of malignant cells: tumour cell depletion in an ex vivo model using a leukocyte adhesion ...